Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 488 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
488 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors harboring specified KRAS mutations or eligible KRAS amplification receive intravenous ASP5834, an investigational agent designed to degrade mutant or amplified KRAS. Patients with KRAS-mutated colorectal adenocarcinoma may receive ASP5834 with panitumumab, an anti-EGFR antibody.
ClinicalTrials.gov ID: NCT07094204
TrialFetch AI summary: Adults with advanced solid tumors and ECOG 0–1 receive once-daily oral NXP900, a SRC-family kinase inhibitor targeting YES1 and SRC. Dose escalation enrolls patients without an appropriate available therapy; dose expansion enrolls patients with selected molecular alterations after 1–3 prior therapies.
ClinicalTrials.gov ID: NCT05873686
TrialFetch AI summary: This trial enrolls previously treated patients with unresectable locally advanced, recurrent, or metastatic NSCLC, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, or left-sided colorectal cancer; prior treatment with a topoisomerase I inhibitor–payload ADC is excluded. All participants receive ALX2004, an investigational EGFR-targeting antibody–drug conjugate with a topoisomerase I inhibitor payload, at a dose determined by the study stage.
ClinicalTrials.gov ID: NCT07085091
TrialFetch AI summary: Adults with measurable, locally advanced or metastatic KRAS-mutant or KRAS-amplified solid tumors who have no remaining standard treatment options or have declined them receive oral AMG 410, a reversible pan-KRAS inhibitor, alone or with the PD-1 inhibitor pembrolizumab. Patients with colorectal or pancreatic cancer may receive AMG 410 with the EGFR-targeting antibody panitumumab.
ClinicalTrials.gov ID: NCT07094113
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic GIST after imatinib, extensive-stage SCLC, or selected c-Kit–associated tumors after standard therapy or when standard therapy is not an option receive intravenous NN3201 every three weeks. NN3201 is an investigational antibody–drug conjugate targeting c-Kit that delivers the cytotoxic payload MMAE.
ClinicalTrials.gov ID: NCT06805825
TrialFetch AI summary: Adults with measurable locally advanced or metastatic small cell lung cancer or pulmonary large cell neuroendocrine carcinoma after platinum-based chemotherapy receive 225Ac-ABD147, an investigational DLL3-targeted antibody fragment that delivers alpha-emitting actinium-225 to tumor cells. Some patients also receive 111In-ABD147 for imaging and dosimetry.
ClinicalTrials.gov ID: NCT06736418
TrialFetch AI summary: Adults with progressive, measurable, unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior peptide receptor radionuclide therapy receive up to four doses of [212Pb]VMT-α-NET, an SSTR2-targeting radiopharmaceutical that delivers lead-212 alpha-particle radiation to tumors. IV renoprotective amino acids are given before each dose.
ClinicalTrials.gov ID: NCT05636618
TrialFetch AI summary: Patients with incurable locally advanced, recurrent, or metastatic solid tumors who lack appropriate standard treatment receive once-daily oral CP-383, an investigational dual DHODH/TEAD4 inhibitor. Dose expansion focuses on selected cancers, including colorectal, small-cell lung, and head and neck cancers, with some cohorts defined by tumor alterations.
ClinicalTrials.gov ID: NCT07030257
TrialFetch AI summary: Adults with measurable advanced bladder, lung, head and neck, esophageal, or pancreatic cancer and ECOG 0–1 receive intravenous PF-08046876, an antibody–drug conjugate targeting integrin beta-6 that delivers a camptothecin-class topoisomerase I inhibitor. Dose escalation requires progression after standard therapy; dose optimization and expansion cohorts allow up to two prior systemic therapy lines for advanced disease.
ClinicalTrials.gov ID: NCT07090499
TrialFetch AI summary: Adults with advanced or metastatic NSCLC, SCLC, endometrial cancer, or triple-negative breast cancer who have received or declined standard therapy, or have no standard options, receive IV LY4175408. This investigational antibody–drug conjugate targets PTK7 and delivers exatecan, a topoisomerase I inhibitor.
ClinicalTrials.gov ID: NCT07046923